

Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate

Laurent Bonello, MD,* Udaya S. Tantry, PhD,§§ Rossella Marcucci, MD, PhD,||
Ruediger Blindt, MD,# Dominick J. Angiolillo, MD, PhD,||| Richard Becker, MD,¶¶
Deepak L. Bhatt, MD, MPH,## Marco Cattaneo, MD,¶ Jean Philippe Collet, MD, PhD,‡
Thomas Cuisset, MD,† Christian Gachet, MD, PhD,§ Gilles Montalescot, MD, PhD,‡
Lisa K. Jennings, PhD,*** Dean Kereiakes, MD,††† Dirk Sibbing, MD,**
Dietmar Trenk, PhD,†† Jochem W. Van Werkum, MD, PhD,‡‡ Franck Paganelli, MD,*
Matthew J. Price, MD,‡‡‡ Ron Waksman, MD,§§§ Paul A. Gurbel, MD,§§
for the Working Group on High On-Treatment Platelet Reactivity

Marseille, Paris, and Strasbourg, France; Florence, and Milano, Italy; Aachen, Munich, and Bad Krozingen, Germany; Nieuwegein, the Netherlands; Baltimore, Maryland; Jacksonville, Florida; Durham, North Carolina; Boston, Massachusetts; Memphis, Tennessee; Cincinnati, Ohio; La Jolla, California; and Washington, DC

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplatelet therapy, including stent thrombosis, remains a major concern. Platelet function measurements during clopidogrel treatment demonstrated a variable and overall modest level of P2Y₁₂ inhibition. High on-treatment platelet reactivity to adenosine diphosphate (ADP) was observed in selected patients. Multiple studies have now demonstrated a clear association between high on-treatment platelet reactivity to ADP measured by multiple methods and adverse clinical event occurrence. However, the routine measurement of platelet reactivity has not been widely implemented and recommended in the guidelines. Reasons for the latter include: 1) a lack of consensus on the optimal method to quantify high on-treatment platelet reactivity and the cutoff value associated with clinical risk; and 2) limited data to support that alteration of therapy based on platelet function measurements actually improves outcomes. This review provides a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and proposes how this measurement may be used in the future care of patients.

Platelet activation and aggregation play pivotal pathophysiological roles in the development of ischemic events during and after acute coronary syndromes (ACS) and percutaneous coronary interventions (PCIs) (1). Adenosine diphosphate (ADP) is a major secondary agonist released from the dense granules of platelets activated by primary agonists (Fig. 1). The ADP-P2Y₁₂ receptor interaction plays a central role in the sustained activation of glycoprotein (GP) IIb/IIIa receptors leading to stable platelet-rich thrombus generation at the site of vessel wall injury (2). Therefore, clopidogrel, whose active metabolite irreversibly inhibits the P2Y₁₂ receptor, is a cornerstone of oral antiplatelet therapy in the secondary prevention of coronary artery disease and in the immediate treatment of ACS and PCI (3).

A significant reduction in ischemic complications in a wide range of coronary artery disease patients has been demonstrated in major randomized controlled trials by adding clopidogrel to aspirin treatment (4,5). The fixed dose, “one size fits all” treatment strategy with clopidogrel therapy, which has been used in clinical trials and recommended by current guidelines, does not take into account the interindividual pharmacodynamic variability of clopidogrel therapy (4–6). Moreover, despite the relatively potent antiplatelet effect of clopidogrel in some patients, others will suffer therapeutic failure manifested by ischemic events, including stent thrombosis, that have been associated with high on-treatment platelet reactivity (7).

These observations have stimulated intensive research of the pharmacodynamic and pharmacokinetic properties of

clopidogrel. Studies measuring platelet function in patients administered clopidogrel revealed that, unlike aspirin and GP IIb/IIIa receptor blocker therapies that are associated with a uniform and high level of inhibition (~95%) of their targets (COX-1 enzyme and GP IIb/IIIa receptor, respectively) with appropriate dosing in particular for GP IIb/IIIa inhibitors, clopidogrel treatment is associated with an overall variable and modest level of P2Y₁₂ inhibition even when high loading doses are used (4,6,8–10). In addition to distinct response variability, a substantial percentage of patients will also exhibit complete nonresponsiveness (resistance) to clopidogrel (10).

Multiple studies now have demonstrated a relationship between clopidogrel nonresponsiveness and/or high on-treatment platelet reactivity measured by multiple platelet assays and adverse clinical ischemic events (7). However, due to a lack of consensus on the optimal methods to quantify high platelet reactivity and the cutoff values associated with clinical risk, the routine measurement of platelet reactivity has not been widely implemented in clinical practice nor recommended in the guidelines (11). In addition, there are only limited data to support the concept that alterations of therapy based on platelet function measurements improve clinical outcome (7).

Herein, we provide a comprehensive overview of the available data that have identified high on-treatment platelet reactivity to ADP as a risk factor for post-PCI ischemic/thrombotic events as well as a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on the primary methods reported in the literature.

Clopidogrel Metabolism


Clopidogrel is a prodrug that requires hepatic conversion into an active metabolite to exert its antiplatelet response. Most of absorbed clopidogrel (~85% to 90%) is hydrolyzed by carboxylase to an inactive carboxylic acid metabolite, SR26334, whereas the remaining ~10% to 15% is rapidly metabolized by hepatic cytochrome (CYP) P450 isoenzymes in a 2-step process. In the first step, the thiophene ring of clopidogrel is oxidized to 2-oxo-clopidogrel, which is then hydrolyzed to a highly labile active metabolite, R-130964, that has both carboxylic acid and thiol groups (12–14). Recent studies indicate that CYP2C19, CYP1A2, and CYP2B6 participate in the first metabolic step, whereas CYP2C19, CYP2C9, CYP2B6, and CYP3A are responsible for the second step (12,13) (Fig. 2). The highly unstable active metabolite, R-130964, covalently binds to platelet P2Y₁₂ receptor specifically and irreversibly during passage through the hepatic circulation resulting in inhibition of ADP-induced platelet activation-aggregation for the life span of the platelet (15). This metabolic activation scheme

From the *Department of Cardiology, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMRS) 608, Hôpital Universitaire Nord, Faculté de Médecine, Marseille, France; †Department of Cardiology, Centre Hospitalier Universitaire (CHU) Timone, Marseille, France; ‡Institut de Cardiologie, CHU Pitié Salpêtrière, Paris, France; §UMRS 949 INSERM, Université de Strasbourg, Etablissement Français du Sang-Alsace, Strasbourg, France; ||Center for Atherothrombotic Diseases Department of Medical and Surgical Critical Area, University of Florence, Florence, Italy; ¶Unità di Medicina III, Ospedale San Paolo, Università degli Studi di Milano, Milano, Italy; #Department of Cardiology, University Hospital Aachen, Aachen, Germany; **Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum, rechts der Isar, Technische Universität München, Munich, Germany; ††Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; †††Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; §§Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland; |||Division of Cardiology, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida; ¶¶Divisions of Cardiology and Hematology, Duke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina; ##VA Boston Healthcare System and Brigham and Women's Hospital, Boston, Massachusetts; ***University of Tennessee Health Science Center, Memphis, Tennessee; ††††The Christ Hospital Heart and Vascular Center/The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio; †††††Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California; and the §§§§Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC. For full author disclosures, please see the end of this paper.

Manuscript received January 15, 2010; revised manuscript received March 30, 2010, accepted April 5, 2010.

Figure 1

Central Role of ADP-P2Y₁₂ Receptor Interaction in Platelet Activation and Aggregation



Central role of adenosine diphosphate P2Y₁₂ receptor interaction in platelet activation and aggregation during occurrence of ischemic events and stent thrombosis. After plaque rupture, tissue factor and collagen are exposed leading to platelet activation. Three important pathways (thrombin-PAR-1 receptor, thromboxane A₂-TP receptor, and adenosine diphosphate P2Y₁₂ receptor) amplify the response. The adenosine diphosphate P2Y₁₂ interaction plays a central role. ADP = adenosine diphosphate; PCI = percutaneous coronary intervention; TxA₂ = thromboxane A₂.

is consistent with the time-dependent cumulative inhibition of ADP-induced platelet aggregation as observed with repeated daily dosing of clopidogrel and is further highlighted by slow recovery of platelet function following drug withdrawal (4,16,17).


Multiple lines of evidence strongly suggest that variable and insufficient active metabolite generation are the primary explanations for clopidogrel response variability and nonresponsiveness, respectively (9). Variable levels of active metabolite generation following clopidogrel administration could be explained by: 1) variable or limited intestinal absorption, which may be affected by an *ABCB1* gene polymorphism (18–20); 2) functional variability in P450 isoenzyme activity influenced by drug-drug interactions as well as other factors; and 3) single nucleotide polymorphisms of specific genes encoding CYP450 isoenzymes (21,22). Stimulation of CYP3A4 activity by rifampin and St. John's wort and CYP1A2 activity by tobacco smoking have both been shown to enhance platelet inhibition induced by clopidogrel (23–25). The effect of smoking on the antiplatelet effect of clopidogrel has been associated with clinical outcomes and may, in part, explain the “smoker's

paradox” (26,27). Conversely, agents that compete with clopidogrel for CYP and/or inhibit CYP attenuate the antiplatelet effect of clopidogrel. A diminished pharmacodynamic response to clopidogrel has been observed with coadministration of proton pump inhibitors, lipophilic statins, and calcium-channel blockers that are metabolized by the CYP2C19 and CYP3A4 isoenzymes (21,28–31). Although a diminished level of platelet inhibition induced by clopidogrel has been demonstrated in some *ex vivo* studies following coadministration of these agents, the consequence of these interactions with respect to ischemic events remains controversial.

Recent studies have evaluated the influence of the single nucleotide polymorphisms of genes encoding CYP2C19 isoenzymes with different activities, as well as single nucleotide polymorphisms of the p-glycoprotein transporter gene on clopidogrel response variability and clinical outcomes (22,32). Multiple independent studies have demonstrated a link between the presence of genetic polymorphisms associated with suboptimal clopidogrel active metabolite generation (pharmacokinetic measurement), decreased clopidogrel responsiveness as measured by platelet function assays (pharmacodynamic measurement), and adverse clin-

Figure 2

Clopidogrel Response Variability



Clopidogrel response variability is a pharmacokinetic problem primarily influenced by the activity of cytochrome P450 isoenzymes in the generation of the active metabolite. Absorption may be affected by polymorphism of the *ABCB1* gene. The activity of hepatic cytochrome isoenzymes are influenced by drug-drug interactions, single nucleotide polymorphisms, and environmental influences (smoking).

ical outcomes. No single study has conclusively associated all of these parameters in the same patient population. Moreover it was observed that other genetic determinants may be involved and that overall, ~12% of the variation in the response to clopidogrel can be attributed to the *CYP2C19**2 loss-of-function allele (33). At this time, it is uncertain whether the factors associated with a poor response to clopidogrel are additive in diminishing the antiplatelet effect of clopidogrel and worsening patient outcomes.

The controversy surrounding the diminished effectiveness of clopidogrel in poor metabolizers (those having 2 loss-of-function *CYP2C19* alleles) and the utility of genetic tests to identify differences in *CYP2C19* function has been recently highlighted by the “boxed warning” issued by the Food and Drug Administration advising health care professionals to consider use of other antiplatelet medications or alternative dosing strategies for clopidogrel in these patients (34). The preceding statement was based on observations from a study of 40 healthy subjects that poor metabolizers had diminished active metabolite exposure and higher platelet aggregation. Although it is believed that the loss-of-function

allele confers its clinical risk by affecting the pharmacodynamic response to clopidogrel, no single study thus far has demonstrated a conclusive link between the presence of a loss-of-function genetic polymorphism, suboptimal clopidogrel active metabolite generation (pharmacokinetic measurement), decreased clopidogrel responsiveness (pharmacodynamic measurement), and adverse clinical outcomes. The warning only addresses patients with 2 loss-of-function alleles. No information is provided for heterozygotes. Earlier Simon *et al.* (18) suggested that increased ischemic risk is confined to homozygotes. Other studies involving patients treated with stenting found a significant relation between ischemic risk and loss-of-function allele carriers (homozygotes and heterozygotes) (33,35–38). The picture is even more confusing with the recently presented CHARISMA (Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance) Genomics substudy (39) results that showed an increase in the combined end point of cardiovascular death, myocardial infarction, and stroke in poor metabolizers (*/*2) compared with wild-type carriers (wt/wt) treated with clopidogrel. Unlike the latter studies,

CHARISMA investigated a lower-risk population and was not a study of stented patients. The CHARISMA Genomics study investigators pointed out 2 important caveats: 1) poor metabolizers in the placebo arm also had an increased risk; but 2) only a small number of primary events occurred in poor metabolizers (placebo arm, $n = 5$ [8.77%] and clopidogrel arm, $n = 8$ [13.79%]). The CHARISMA Genomics study (39) is the only investigation in which the influence of genotyping on clinical outcome was studied in both the clopidogrel arm and the placebo arm.

Moreover, the safety and efficacy of altering therapy in response to genotype is entirely unknown. Whereas neither genotyping nor platelet function tests alone adequately describe the global risk profile of an individual patient treated with clopidogrel, point-of-care platelet function testing to identify high-risk patients combined with CYP2C19 genetic testing may be more effective in identifying high-risk individuals for alternative antiplatelet therapies. Ultimately, prospective randomized clinical trials will be needed to test specific personalized antiplatelet algorithms to provide the evidence base necessary for widespread adoption into clinical practice.

In addition to the preceding mechanisms for clopidogrel pharmacodynamic variability, increased body mass index, diabetes mellitus, and acute coronary syndromes have also been associated with a diminished antiplatelet response to clopidogrel (40–42). Several studies have demonstrated the coexistence of clopidogrel and aspirin resistance in the same patient population (43,44). It has also been demonstrated that patients with low responsiveness to a 600-mg loading dose, in addition to exhibiting a low level of inhibition of ADP-induced aggregation, also exhibit lower inhibition of aggregation induced by collagen and thrombin receptor agonist peptide as compared to moderate and high clopidogrel responders (45). Taken together, these data support the existence of a “hypo-responsive” or global high platelet-reactivity phenotype. Patients with the latter phenotype will have platelets that react robustly to multiple agonists. Finally, noncompliance is an obvious factor that must be excluded in the diagnosis of clopidogrel nonresponsiveness. When attempting to define causality for high platelet reactivity related to the occurrence of clinical events in patients receiving clopidogrel, all of the aforementioned mechanisms should be considered.

Concept of Clopidogrel Nonresponsiveness, Resistance, and High On-Treatment Platelet Reactivity

A single treatment strategy directed against a specific receptor cannot be expected to overcome all thrombotic events, and clinical treatment failure (occurrence of an

ischemic event) during clopidogrel treatment is not synonymous with clopidogrel resistance. The optimal definition of resistance or nonresponsiveness to any antiplatelet agent should be the failure of the antiplatelet agent to inhibit the target of its action (7). The identification of resistance should therefore utilize a laboratory technique that detects the activity of the target receptor before and after administration of the specific antiplatelet agent. For example, the absence of a change in platelet response (reactivity) to ADP from baseline after clopidogrel intake is an indicator of clopidogrel resistance. Earlier studies that measured light transmission platelet aggregation used an absolute difference of $\leq 10\%$ aggregation as the definition of clopidogrel resistance (baseline vs. on-treatment) (6,7). Patients were also categorized as “nonresponsive,” “semiresponsive,” and “responsive” using absolute platelet inhibition cut points of $< 10\%$, 10% to 30%, and $> 30\%$, respectively (6,46).

Even though a measurement of responsiveness (absolute or relative changes in platelet aggregation from baseline) appears as the most reliable indicator of a treatment effect, it may not be the optimal method to identify patients at high risk. Given the interindividual variability in baseline ADP-induced platelet aggregation, the measurement of clopidogrel responsiveness (inhibition) may overestimate ischemic risk in nonresponders with low pre-treatment reactivity as well as underestimate risk in responders who remain with high platelet reactivity after treatment (47,48). Therefore, the absolute level of platelet reactivity during treatment (i.e., on-treatment platelet reactivity) has been proposed as a better measure of thrombotic risk than responsiveness to clopidogrel.

The relationship of on-treatment platelet reactivity to both periprocedural and long-term ischemic risk has been most widely investigated. However, the optimal method to quantify platelet reactivity as well as the threshold definition for high on-treatment platelet reactivity to ADP have been subjects of controversy. Another concern surrounds the timing of platelet reactivity measurement that is optimally associated with short- and long-term risk. Any definition of high on-treatment platelet reactivity will only be meaningful when a cutoff or target value is identified by an accepted statistical test. Most commonly, the receiver-operator characteristic (ROC) curve analysis has been used to define the optimal cut point definition of high on-treatment platelet reactivity associated with ischemic risk. This method allows us to determine the cutoff value of platelet reactivity that would be associated with the lowest false negative and false positive rates and thus provides the greatest sum of sensitivity and specificity. The ROC curve analysis has been used to define cut points currently employed in prospective studies of individualized antiplatelet therapy in PCI patients (49).

Methods to Assess Platelet Responsiveness to ADP and P2Y₁₂ Receptor Reactivity

Because clopidogrel specifically inhibits the P2Y₁₂ receptor, ex vivo measurement of ADP-induced platelet aggregation in platelet-rich plasma by light transmittance aggregometry has been the most commonly used laboratory method to evaluate platelet inhibition by clopidogrel and its relation to ischemic risk. In the strictest sense, aggregometry evaluates an integrated response of the platelet to ADP through the function of both P2Y₁ and P2Y₁₂ receptors. In most studies, the maximal amplitude of measured platelet aggregation in response to 5-, 10-, or 20- $\mu\text{mol/l}$ ADP has been recorded. Citrate remains the most widely used anticoagulant during platelet function testing, although it affects intracellular calcium ion concentrations, which may influence platelet function. Alternatively, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone or hirudin may be used to reduce changes in calcium ion concentrations. In addition to maximum platelet aggregation, late (final or residual) aggregation measured 5 to 6 min after the addition of agonist, a time when platelet disaggregation normally appears, has been proposed as a better indicator of clopidogrel responsiveness. Although Collet et al. (20) and Labarthe et al. (50) have correlated late aggregation with the antiplatelet response to clopidogrel, Gurbel et al. (51) suggested that clopidogrel nonresponders may be similarly identified by both maximal and late aggregation. Although some investigators have advocated the adjustment of platelet concentration in plasma to $\sim 250,000/\text{mm}^3$ before measuring, others have suggested that such an adjustment may introduce artifacts and contribute to assay variability (52). Unfortunately, because many other procedures involved in the performance of light transmittance aggregometry are not standardized between institutions, light transmittance aggregometry may not be the ideal test to monitor the effects of antiplatelet therapy outside of clinical trials (53).

Flow cytometric measurements of platelet expression of both activated GP IIb/IIIa receptor and P-selectin (CD62) following ADP stimulation in addition to ADP-induced platelet-fibrin clot strength as measured by whole blood thrombelastography have also been used to identify clopidogrel nonresponsiveness. Thrombelastography measurements correlated platelet function with ischemic risk in the PCI population (54,55). In addition, 2 point-of-care whole blood assays, the VerifyNow P2Y₁₂ assay (Accumetrics, San Diego, California) and the Multiplate analyzer (Dynabyte Informationssysteme, Munich, Germany) (both employing ADP as the agonist) have been used to measure platelet reactivity during clopidogrel therapy. The VerifyNow P2Y₁₂ assay is a turbidimetric assay that measures aggregation of platelets to fibrinogen-coated beads in whole blood. The

Multiplate analyzer is an impedance aggregometer that assesses platelet function in whole blood. The platelet function analyzer PFA-100 (Dade Behring, Deerfield, Illinois) method, which utilizes collagen/ADP-based cartridges and measures shear-induced platelet aggregation, has been associated with inconsistent estimates of platelet reactivity to ADP. Finally, the phosphorylation state of vasodilator-stimulated phosphoprotein (VASP) is a specific intracellular marker of residual P2Y₁₂ receptor reactivity in patients treated with P2Y₁₂ blockers, which is currently measured by flow cytometry and has also been correlated with ischemic risk (7). In addition, this is the only test that specifically assesses P2Y₁₂ receptor activity. Unlike methods employing the aggregation induced by ADP, in VASP, phosphorylation assay measurement does not include the contribution of the P2Y₁ receptor to the overall response (56).

Clopidogrel Nonresponsiveness and On-Treatment Platelet Reactivity: Early Studies

Järemo et al. (57) first reported interindividual variability in response to clopidogrel in patients with coronary artery disease by using flow cytometry to detect ADP-induced fibrinogen binding to platelets. Gurbel et al. (6) first demonstrated clopidogrel response variability and resistance using conventional platelet aggregometry and flow cytometry studies in patients undergoing PCI who had received a 300-mg loading dose followed by 75-mg daily maintenance dose of clopidogrel. The level of platelet inhibition induced by clopidogrel was dependent on the time after clopidogrel treatment when platelet function was measured and the prevalence of resistance fell from 31% (days 1 and 5) to 15% (day 30). Importantly, although a 600-mg clopidogrel loading dose is associated with more potent platelet inhibitory effects than a 300-mg dose, this higher-dose regimen was not able to completely overcome resistance, and a broad variability in response profiles continued to persist (8,9). In the Gurbel et al. studies (6,8), pharmacologic resistance to clopidogrel was defined as an absolute $\leq 10\%$ decrease in platelet aggregation in response to agonist from baseline (pre-treatment measurement). Based on these studies, it became similarly apparent that the level of post-treatment platelet reactivity during clopidogrel therapy was largely unpredictable. Only early platelet reactivity (24 h after PCI) correlated with pre-treatment platelet reactivity (6).

Link Between High Platelet Reactivity and Post-PCI Ischemic/Thrombotic Events

Numerous studies have reported pharmacological “resistance” to clopidogrel as a potential etiology for thrombotic events after PCI (Table 1) (43,54–83). Barragan et al. (58)

were the first to demonstrate an association between post-treatment platelet reactivity and the occurrence of thrombotic events (clinical treatment failure) in a case-control study of PCI patients. In the study by Barragan *et al.* (58), a platelet reactivity index (PRI) >50% measured by VASP-phosphorylation assay was associated with thrombotic risk. Of note, in this study, turbidimetric aggregation was not associated with ischemic risk. However, at the same time, Matetzky *et al.* (59), using aggregometry, observed that patients undergoing primary PCI for ST-segment elevation myocardial infarction who were in the lowest quartile of clopidogrel responsiveness had the highest rates of ischemic events during follow-up.

Subsequently, it was suggested that the level of on-treatment platelet reactivity might be a superior risk predictor compared with the difference between baseline and post-treatment platelet reactivity, because platelet reactivity to ADP was variable before clopidogrel treatment in patients on aspirin therapy (47,48). The important relationship between high on-treatment platelet reactivity to ADP as measured by turbidimetric aggregometry and the occurrence of ischemic events in patients treated with stents was first prospectively demonstrated in the PREPARE POST-STENTING (Platelet Reactivity in Patients and Recurrent Events Post-Stenting) study (upper quartile, odds ratio: 2.6) (55). Multiple subsequent studies have confirmed the direct relationship between the level of platelet reactivity and post-PCI ischemic event occurrence using aggregation. Most recently, there have been further studies employing the VASP-phosphorylation assay, the VerifyNow P2Y₁₂ assay, and the Multiplate analyzer. These studies have consistently demonstrated that high on-treatment platelet reactivity is an important independent risk factor for the occurrence of thrombotic/ischemic events after PCI (56–84).

High Platelet Reactivity Defined by ROC Analysis

Importantly, studies have emerged that have used ROC curve analysis to define a threshold or cut point of on-treatment platelet reactivity associated with the optimal combination of sensitivity and specificity to identify thrombotic risk (Table 2). Thrombotic events may be prevented by achieving platelet reactivity below this threshold. It should be noted that such cut points might depend on the subset of patients studied. In fact, to date, cutoff values have been mainly investigated in patients undergoing PCI and different targets may be obtained in other settings depending on patient management or baseline risk profile (77,78).

Recent studies (62,64,72,76,77) have observed the prognostic value of the VASP phosphorylation analysis,

with an optimal cutoff value for VASP-PRI between 48% and 53%, which is similar to the threshold defined by Barragan *et al.* (58) in their earlier study of early stent thrombosis. Although these studies used different ischemic end points such as stent thrombosis or major adverse cardiac events (e.g., cardiovascular death, myocardial infarction, and urgent revascularization with or without stroke), they nevertheless found similar cutoff values for the VASP-PRI that were associated with post-PCI thrombotic event occurrence. Similarly, using the VerifyNow P2Y₁₂ assay, a cutoff value of ~240 P2Y₁₂ reaction units appears to be prognostic for subsequent thrombotic events (including cardiovascular death and stent thrombosis or cardiovascular death, nonfatal myocardial infarction, and stent thrombosis) (68,78,79,82). In a recent study, maximal platelet aggregation >46% in response to 5- μ mol/l ADP following PCI was associated with major adverse cardiac events (69). Using the Multiplate analyzer, Sibbing *et al.* (80) demonstrated that high on-treatment ADP-induced platelet reactivity measured before PCI was associated with the occurrence of 30-day stent thrombosis in 1,608 patients who had received a 600-mg clopidogrel loading dose before PCI. Moreover, based on ROC analysis, a cut point of 468 arbitrary aggregation units/min (approximately corresponding to the highest quintile) was associated with the occurrence of stent thrombosis (80). Recently, Breet *et al.* (82) evaluated the utility of multiple platelet function assays in predicting 1-year outcome of death, myocardial infarction, stent thrombosis, and stroke in 1,069 consecutive patients treated with clopidogrel following elective coronary stent implantation. In this large, prospective, observational study, high on-treatment platelet reactivity cut points of 42.9% maximal aggregation induced by 5- μ mol/l ADP and 64.5% by 20- μ mol/l ADP light transmittance aggregometry; 236 P2Y₁₂ reaction units measured by VerifyNow P2Y₁₂ assay; and 80.5% aggregation by Plateletworks (Helena Laboratories, Beaumont, Texas) all correlated with the occurrence of the composite primary end point, with an area under the curve of ~0.62 for each assay. The addition of high on-treatment platelet reactivity as measured by the noted platelet assays to more classical clinical and procedural risk factors improved the area under the curve to ~0.73 (82).

Each of these studies may thus provide a target level of platelet reactivity for future investigations, similar to the international normalized ratio used for warfarin therapy. The consistent findings across multiple investigations support the crucial role of high on-treatment reactivity in the etiology of ischemic events after PCI, including stent thrombosis, and suggest the existence of a threshold level of platelet reactivity below which ischemic events may be prevented

Table 1

Studies Linking High On-Treatment Platelet Reactivity to ADP and Clopidogrel Nonresponsiveness to Post-PCI Adverse Clinical Event Occurrence

Study (Ref. #)	Patients (n)	Treatment	Methods	Definition	Clinical Relevance
Barragan et al. (58)	PCI (46)	250 mg qd TLP or CLP 75 mg qd	VASP-PRI	>50% VASP-PRI	↑ ST
Gurbel et al. (55)	Elective PCI (192)	300-mg LD + 75 mg qd CLP +/- EPT	5-μmol/l ADP-LTA	HPR = 75th percentile post-PCI aggregation	↑ 6-month post-PCI events, OR: 2.7
Matetzky et al. (59)	PCI/STEMI (60)	300-mg LD + 75 mg qd CLP +/- EPT	5-μmol/l ADP-LTA	Reduction in platelet aggregation Upper quartile	↑ 6-month cardiac events
Gurbel et al. (60)	Elective PCI (120)	300-mg LD CLP +/- EPT	5-μmol/l ADP-LTA	Mean periprocedural platelet aggregation >50%	↑ Periprocedural myonecrosis
Gurbel et al. (61)	Elective PCI (200)	300-/600-mg LD CLP +/- EPT	5-μmol/l ADP-LTA	Mean periprocedural platelet aggregation >40%	↑ Periprocedural myonecrosis
Bliden et al. (54)	Elective PCI (100)	75 mg qd CLP	5-μmol/l ADP-LTA	>50% platelet aggregation	↑ 1-yr post-PCI events
Lev et al. (43)	Elective PCI (150)	300-mg CLP LD	5- and 20-μmol/l ADP-LTA	Baseline—post-treatment aggregation ≤10%	↑ Periprocedural myonecrosis
Blindt et al. (62)	High risk for ST/PCI (99)	75 mg qd for 6 months	VASP-PRI (72–96 h after stenting)	>48% PRI (ROC)	↑ 6-month ST
Cuisset et al. (63)	NSTEMI/ACS/PCI (190)	600-mg CLP LD >6 h before PCI	10-μmol/l ADP-LTA VASP-PRI	HPR >70% post-treatment LTA	↑ Periprocedural myonecrosis
Frere et al. (64)	NSTEMI/ACS/PCI (195)	600-mg CLP LD >6 h before PCI	10-μmol/l ADP-LTA	HPR (ROC) >70% post-treatment LTA >53% VASP-PRI	↑ 30-day post-PCI events MACE + stroke
Geisler et al. (65)	CAD/PCI (379)	600-mg CLP LD >6 h before PCI	20-μmol/l ADP-LTA	Clopidogrel low responders = <30% platelet inhibition	↑ 3-month MACE and death OR: 4.9
Geisler et al. (66)	CAD/PCI (1,092)	600-mg CLP LD >6 h before PCI + 75 mg qd	20-μmol/l ADP-LTA Residual aggregation measured after 5 min	Upper quartile	↑ 30-day MACE
Hochholzer et al. (67)	Elective PCI (802)	600-mg CLP LD >2 h before PCI + 75 mg qd	5-μmol/l ADP-LTA Residual aggregation measured after 5 min	Platelet aggregation above median	↑ 30-day MACE OR: 6.7
Price et al. (68)	PCI (380)	600-mg CLP LD >12 h before PCI or 75 mg qd >5 days	VerifyNow P2Y12 assay	HPR = post-treatment ≥235 PRU (ROC)	↑ 6-month post-PCI events including ST
Gurbel et al. (69)	Elective PCI (297)	300-/600-mg LD/ 75 mg qd CLP +/- EPT	5- and 20-μmol/l ADP-LTA	HPR = post-procedural (ROC) >46% 5-μmol/l ADP >59% 20-μmol/l ADP	↑ 2-yr ischemic events 5-μmol/l ADP OR: 3.9 20-μmol/l ADP OR: 3.8
Gurbel et al. (70)	Stenting (120)	75-mg qd CLP >5 days	5- and 20-μmol/l ADP-LTA	HPR >75th percentile of platelet reactivity 5-μmol/l ADP = 50% 20-μmol/l ADP = 65%	↑ ST
Buonamici et al. (71)	PCI/DES (804)	600-mg LD + 75 mg qd for 6 months	10-μmol/l ADP-LTA	HPR ≥70% aggregation	↑ ST HR: 3.08
Bonello et al. (72)	PCI/stenting (144)	300-mg LD >24 h	VASP-PRI	>50% PRI (ROC)	↑ 6-month post-PCI MACE
Cuisset et al. (73)	PCI/SA (120)	600-mg LD ≥12 h before PCI	VerifyNow P2Y12 assay	↑ Platelet reactivity	↑ Post-PCI myonecrosis

continued on next page

Table 1

Continued

Study (Ref. #)	Patients (n)	Treatment	Methods	Definition	Clinical Relevance
Migliorini et al. (74)	PCI/DES/ULMD (215)	600-mg LD + 75 mg qd for 12 months	10- μ mol/l ADP-LTA	HPR \geq 70% aggregation	\uparrow 3-yr cardiac death and ST HR CV death: 3.82 HR ST: 3.69
Marcucci et al. (75)	PCI/ACS (683)	600-mg LD + 75 mg qd	VerifyNow P2Y ₁₂ assay	HPR \geq 240 PRU	12-month ischemic event HR CV death: 2.55 HR nonfatal MI: 3.36
Bonello et al. (76)	PCI/stenting (162)	600 mg repeated dose until PRI <50%	VASP-PRI	<50% VASP-PRI	\downarrow 1-month ischemic event
Bonello et al (77)	PCI/stenting (214)	600-mg repeated dose until PRI <50%	VASP-PRI	<50% VASP-PRI	\downarrow Early ST and MACE (OR: 9.4)
Valgimigli et al. (78)	Elective PCI (1,277)	600-mg LD before PCI	VerifyNow aspirin and P2Y ₁₂ assay	>235 PRU >550 ARU	\uparrow Post-PCI myonecrosis
Patti et al. (79)	PCI (160)	600-mg LD or 75 mg qd >5 days	VerifyNow P2Y ₁₂ assay	HPR \geq 240 PRU (Pre-PCI)	\uparrow 1-month major cardiovascular event occurrence
Sibbing et al. (80)	PCI/DES (1,608)	600-mg LD before PCI	6.4- μ mol/l ADP Multiplate analyzer	Upper quintile (>416 AU/min) (ROC)	\uparrow 1-month definite ST (OR: 9.4)
Cuisset et al. (81)	NSTEMI/stenting (598)	600-mg LD \geq 12 h before PCI	10- μ mol/l ADP-LTA VASP-PRI	>67% aggregation (ROC)	\uparrow ST
Breet et al. (82)	Elective PCI (1,069)	75-mg qd >5 days 300-mg LD >1 day 600-mg LD	20- μ mol/l ADP-LTA VerifyNow P2Y ₁₂ 20- μ mol/l ADP Plateletworks Before PCI	>42.9% 5- μ mol/l ADP (ROC) >64.5% 20- μ mol/l ADP >236 PRU 80.5% Plateletworks	OR for 1-yr death, MI, ST, and stroke 5- μ mol/l ADP: 2.09 20- μ mol/l ADP: 2.05 VerifyNow: 2.53 Plateletworks: 2.22

ACS = acute coronary syndromes; ADP = adenosine diphosphate; ARU = aspirin resistance units; AU = arbitrary aggregation units; CAD = coronary artery disease; CLP = clopidogrel; CV = cardiovascular; DES = drug-eluting stent; EPT = eptifibatid; HPR = high on-treatment platelet reactivity; HR = hazard ratio; LD = loading dose; LTA = light transmittance aggregometry; MACE = major adverse cardiac events; MI = myocardial infarction; NSTEMI = non-ST-segment elevated myocardial infarction; OR = odds ratio; PCI = percutaneous intervention; PRU = P2Y₁₂ reaction units; qd = once daily; ROC = receiver-operator characteristic curve; SA = stable angina; ST = stent thrombosis; STEMI = ST-segment elevated myocardial infarction; TLP = ticlopidine; ULMD = unprotected left main disease; VASP-PRI = vasodilator stimulated phosphoprotein—platelet reactivity index.

(62,64,68,69,72,75,80–82). Most importantly, the observed cut-off values for platelet reactivity noted previously had a very high negative predictive value for thrombotic/ischemic event occurrence, an observation of potential great clinical importance. However, the positive predictive value is fairly low for all assays. This is consistent with the fact that although it is a major determinant of thrombotic events, high on-treatment platelet reactivity is not the sole factor responsible for these events.

Personalized Antiplatelet Therapy: Preliminary Prospective Studies

Following the demonstration of a link between high on-treatment platelet reactivity in patients undergoing PCI together and thrombotic/ischemic events, several studies have aimed to lower the level of platelet reactivity by modifying therapy. These studies have demonstrated that platelet reactivity to ADP on standard clopidogrel therapy can be lowered by using higher loading or maintenance

doses of clopidogrel, the addition of cilostazol, switching to more potent alternative P2Y₁₂ receptor blockers such as prasugrel or ticagrelor (AstraZeneca, Wilmington, Delaware), and by adding elinogrel or GP IIb/IIIa inhibitors (76–78,85–93). An improved outcome with altered therapy was observed in some of these studies (76–78,93).

In 2 small multicenter trials that employed the VASP-phosphorylation assay, tailored incremental loading doses of clopidogrel further reduced on-treatment platelet reactivity below the previously noted threshold and were effective in reducing subsequent major adverse cardiac events without increasing Thrombolysis In Myocardial Infarction (TIMI) major or minor bleedings. However, it must be noted that about 5% of patients remain resistant to clopidogrel even after repeated loading doses of 600 mg (76,77). Similarly, following these findings, 2 other studies (82,91) have suggested that the selective administration of platelet GP IIb/IIIa receptor blockers to patients undergoing elective PCI who were identified as

Table 2

Studies Linking High On-Treatment Platelet Reactivity to Ischemic Events Based on ROC Curve With a Specific Cutoff Value

Study (Ref. #)	Assay	Cutoff Value	End Point	AUC	Odds Ratio
Price et al. (68)	VerifyNow P2Y12 assay	>235 PRU	6-month post-PCI CVD + MI + ST	0.71	NA
Gurbel et al. (69)	LTA	>46% 5-μmol/l ADP >59% 20-μmol/l ADP	2-year post-PCI MACE	0.77 0.78	3.9 3.8
Blindt et al. (62)	VASP-PRI	>48% PRI	6-month ST	0.79	1.16
Frere et al. (64)	LTA VASP-PRI	>70% 10-μmol/l ADP >53% PRI	1-month post-PCI MACE + stroke	0.74 0.73	NA
Bonello et al. (72)	VASP-PRI	>50% PRI	6-month post-PCI MACE	0.55	NA
Marcucci et al. (75)	VerifyNow P2Y12 assay	≥240	1-yr CV death and nonfatal MI	0.66	2.38 CV death 2.76 nonfatal MI
Sibbing et al. (80)	Multiplate analyzer-ADP	>468 AU/min 6.4-μmol/l ADP	30-day ST	0.78	12.0
Cuisset et al. (81)	LTA	>67% 10-μmol/l ADP	1-month ST	0.69	5.8
Breet et al. (82)	LTA VerifyNow P2Y12 assay Plateletworks	>42.9% 5-μmol/l ADP >64.5% 20-μmol/l ADP >236 PRU >80.5% 20-μmol/l ADP	1-yr death, MI, ST, and stroke	0.63 0.62 0.62 0.61	2.09 2.05 2.53 2.22

AUC = area under the curve; CVD = cardiovascular disease; NA = not addressed; other abbreviations as in Table 1.

having high on-treatment platelet reactivity following an oral clopidogrel loading dose was effective in reducing subsequent post-PCI ischemic events without increased bleeding rates. These studies are the first to suggest that the cutoff value identifying patients at increased risk of thrombotic events could be used to tailor therapy and lead to an improved outcome.

Ongoing Studies of Personalized P2Y₁₂ Inhibitor Therapy

Larger clinical trials aimed at confirming the potential benefit of tailored doses of clopidogrel according to on-treatment platelet reactivity assessed by VerifyNow are currently recruit-

Table 3

Ongoing Clinical Studies Based Platelet Reactivity Measurement by VerifyNow Assay


Study	ClinicalTrials.gov Identifier	Unstable or NSTEMI/PCI	Outcome	Clopidogrel Therapy	
GRAVITAS	Gauging Responsiveness With a VerifyNow Assay—Impact on Thrombosis and Safety	NCT00645918	Elective or ACS/PCI/DES (2,783)	6-month CV death, nonfatal MI, or ST	75 mg qd vs. 150 mg qd
ARCTIC	Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy	NCT00827411	Elective PCI/DES (2,500)	12-month composite end point of death, MI, stroke, urgent revascularization, ST	Therapy based on MD's performance
DANTE	Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition	NCT00774475	Unstable or NSTEMI/PCI (442)	6- and 12-month CV death, nonfatal MI, TVR by PCI or CABG	75 mg qd vs. 150 mg qd
TOPAS -1	Tailoring of Platelet Inhibition to Avoid Stent Thrombosis	NCT00914368	Previous PCI or stenting for CAD (450)	6-month ST	600-mg LD 75 mg qd for 6 months
TRIGGER-PCI	Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel	NCT00910299	PCI patients (2,150)	CV death, nonfatal MI	Prasugrel 60/10 mg vs. clopidogrel 600/75 mg

CABG = coronary artery bypass graft; MD = maintenance dose; TVR = target vessel revascularization; other abbreviations as in Table 1.

ing patients (Table 3) (94). The clinical benefit of achieving lower levels of on-treatment platelet reactivity was suggested by the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) (95) and the PLATO (Platelet Inhibition and Patient Outcomes) trials (96). In TRITON-TIMI 38, prasugrel, a third-generation thienopyridine associated with faster and lower on-treatment platelet reactivity than clopidogrel, was in turn associated with a lower prevalence of thrombotic events in ACS patients treated with PCI (95,97). However, prasugrel was associated with greater bleeding rates in the TRITON-TIMI 38 trial that may be related to excessively low platelet reactivity in selected patients (97). In the PLATO study, ticagrelor, the first oral nonthienopyridine reversible P2Y₁₂ inhibitor that provides a faster platelet inhibition and lower on-treatment platelet reactivity than clopidogrel was also associated with lower rates of ischemic events in an ACS population. Similar to the results of TRITON-TIMI 38, increased bleedings in ACS patients undergoing PCI were also noted in the ticagrelor group (95–97). These findings are consistent with the hypothesis that lower levels of platelet aggregation are associated with reduced ischemic events but increased bleeding risk. In the PLATO study, a similar bleeding event rate in patients undergoing coronary artery bypass grafting where ticagrelor therapy was discontinued within 3 days before surgery was observed (96). This was supported by the observation that ticagrelor was associated with faster offset of antiplatelet effects compared with clopidogrel therapy despite superior platelet inhibition in the ONSET/OFFSET (Randomized Double-Blind Assessment of the Onset and Offset of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Disease) study (17). Moreover, in the RESPOND (Response to Ticagrelor in Clopidogrel Nonresponders and Responders and the Effect of Switching Therapies) study (93), ticagrelor therapy was associated with uniform and superior platelet inhibition in both previously identified clopidogrel responders and non-responders, and that inhibition, in turn, was associated with an extremely low prevalence of high on-treatment platelet reactivity. In addition, another novel reversible P2Y₁₂ receptor blocker, elinogrel, has been shown to be associated with enhanced platelet inhibition when administered to selected patients with high platelet reactivity during standard clopidogrel therapy. Moreover, the antiplatelet effect of elinogrel was completely reversible within 24 h (92). The previously discussed alternative therapies may provide important advances to attenuated ischemic events occurrence, particularly in selected patients with high platelet reactivity on standard clopidogrel treatment. Dose adjustments based

Figure 3

Post-PCI Ischemic/Thrombotic Clinical Events



The sigmoid cumulative frequency curve in patients with post-percutaneous coronary intervention ischemic/thrombotic clinical events relative to platelet reactivity to adenosine diphosphate. These data support the concept of a therapeutic window for P2Y₁₂ blockade. Adapted, with permission, from Gurbel *et al.* (7). Abbreviation as in Figure 1.

on objective measurements of platelet reactivity may reduce the prevalence of bleeding. Reversibility may facilitate the management of patients requiring unanticipated surgery. The results of TRITON-TIMI 38 and PLATO suggest that there may be a fine balance between ischemic event occurrences and bleeding in patients treated with P2Y₁₂ receptor blockers. Consistently tailored P2Y₁₂ receptor blockade has the potential to improve outcome.

P2Y₁₂ Inhibitor Therapeutic Window

As platelet-mediated ischemic events appear to be clustered in the upper tertile or quartile of on-treatment platelet reactivity (i.e., above the optimal cut points previously identified), there may exist a “therapeutic window” for P2Y₁₂ receptor antagonist therapy that is associated with both an optimal reduction in thrombotic events as well as a low rate of major bleeding. The identification of a specific threshold for platelet reactivity that confers protection against thrombotic events and yet also limits bleeding following PCI is a crucial area of investigation, particularly in light of the increasing availability of platelet point-of-care assays as well as the widening choice of P2Y₁₂ receptor antagonists (7,60) (Fig. 3). At this time, there have been no definitive studies confirming a cut point of platelet reactivity to ADP associated with bleeding risk. However, recent observational data have emerged showing an association of an excessive response to clopidogrel and the occurrence of major

in-hospital bleeding events in clopidogrel-treated patients undergoing PCI (98–100). Moreover, the advent of more potent antiplatelet drugs that target the P2Y₁₂ receptor—such as prasugrel and ticagrelor, sets the need to study the relationship of antiplatelet treatment and risk for bleeding more thoroughly.

Future Considerations

It is unknown whether on-treatment platelet reactivity cut points associated with risk for periprocedural events are the same as those associated with long-term risk. Although similar cut points have been reported, the optimal platelet reactivity target may vary with respect to the time following the PCI procedure. For example, lower on-treatment platelet reactivity may be optimal in the early period following ACS and/or PCI, whereas the same low level may not provide the same clinical advantage 6 months later due to excessive bleeding. Also, the optimal level of platelet reactivity may differ between the settings of elective as compared to emergent PCI. Another factor that must be considered is that antiplatelet therapy responsiveness has been reported to improve over time following PCI, which may result in lower on-treatment platelet reactivity (6). Finally, the comparative utility of platelet function versus genetic testing should be investigated prospectively in order to determine whether these strategies are complementary or stand-alone methods to identify the high-risk patients.

Conclusions

The absolute level of platelet reactivity during treatment (i.e., on-treatment platelet reactivity) is proposed by the consensus of all the authors to be a better measure of thrombotic risk than responsiveness to clopidogrel. Currently available evidence supports the concept of a threshold for on-treatment platelet reactivity that may be used to stratify patient risk for ischemic/thrombotic events following PCI, including stent thrombosis. At the present time, high on-treatment platelet reactivity in the setting of PCI has been defined by ROC analyses using the following criteria: 1) PRI >50% by VASP-P analysis; 2) >235 to 240 P2Y₁₂ reaction units by VerifyNow P2Y₁₂ assay; 3) >46% maximal 5- μ mol/l ADP-induced aggregation; and 4) >468 arbitrary aggregation units/min in response to ADP by Multiplate analyzer (68,69,72,80) (Table 2). However, there are no large-scale clinical studies to date demonstrating that the adjustment of antiplatelet therapy based on any of these cut points improves clinical outcomes. Finally, PCI patients with diabetes and patients with ACS treated medically as compared to those treated with PCI may have different high on-treatment platelet reactivity cut points (84).

Ongoing studies with the VerifyNow P2Y₁₂ assay are underway to determine whether individually tailoring antiplatelet therapy will improve clinical outcomes after PCI. These studies will also investigate the relationship of platelet

reactivity to bleeding events. Currently, platelet function testing may be considered in determining an antiplatelet strategy in patients with a history of stent thrombosis and in patients prior to undergoing high-risk PCI. However, until the results of large-scale trials of personalized antiplatelet therapy are available, the routine use of platelet function measurements in the care of patients with cardiovascular disease cannot be recommended.

Author Disclosures

Dr. Marcucci has received an honorary fee as a consultant for Ely-Lilly. Dr. Angiolillo has received lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, and Daiichi Sankyo, Inc.; honoraria for serving on the advisory boards of Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Daiichi Sankyo Inc., AstraZeneca, The Medicines Company, Portola Pharmaceuticals, Novartis, Medtronic, Accumedics, Arena Pharmaceuticals, Merck, and Evolva Pharmaceuticals; and research grants from GlaxoSmithKline, Otsuka, Boston Scientific, Accumedics, Eli Lilly and Company, Daiichi Sankyo Inc., The Medicines Company, AstraZeneca, Eisai, Portola Pharmaceutical, Schering-Plough, and Johnson & Johnson. Dr. Becker has received research grants from AstraZeneca, Bayer, Bristol-Myers Squibb, Johnson & Johnson, The Medicines Company, Schering-Plough, and Merck and has served on the scientific advisory boards of Eli Lilly and Daiichi Sankyo Inc.; his institution performs clinical research supported by AstraZeneca. Dr. Bhatt has received research grants from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, HeartScape, Sanofi-Aventis, and The Medicines Company. Dr. Cattaneo has received lecture honoraria from Eli Lilly/Daiichi Sankyo Inc., AstraZeneca, and The Medicines Company. Dr. Collet has received research grants from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Fédération Française de Cardiologie, Société Française de Cardiologie, Fondation de France, INSERM, Medtronic, Guerbet Medical, Cordis, and Stago; consultant fees from Sanofi-Aventis, Eli Lilly, and Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly. Dr. Gachet has received research grants from Stago, Sanofi-Aventis, Bristol-Myers Squibb, and Servier and honoraria from Sanofi-Aventis, Bristol-Myers Squibb, Servier, and Eli Lilly, and has also served on the scientific advisory boards of Sanofi-Aventis and Bristol-Myers Squibb. Dr. Montalescot has received research grants from Abbott Vascular, Bristol-Myers Squibb, Boston Scientific, Cordis, Fédération Française de Cardiologie, Société Française de Cardiologie, Fondation de France, Guerbet Medical, INSERM, Medtronic, Sanofi-Aventis, Eli Lilly, Stago, Centocor, ITC Edison, and Pfizer; consulting fees from AstraZeneca, Eisai, Menarini, Novartis, Pfizer, Portola, Schering-Plough, Sanofi-Aventis, Eli Lilly, Bristol-Myers Squibb, The Medicines Company, Daiichi Sankyo Inc., Bayer, and Boehringer Ingelheim; and

lecture fees from Abbott Vascular, Cordis, Menarini, Pfizer, Schering-Plough, Sanofi-Aventis, Eli Lilly, Bristol-Myers Squibb, Merck Sharpe and Dohme, GlaxoSmithKline, Accumetrics, AstraZeneca, and Daiichi Sankyo Inc. Dr. Jennings has served as a consultant for AstraZeneca, Daiichi Sankyo Inc., Schering-Plough/Merck, Sanofi-Aventis/Bristol-Myers Squibb, and Portola; has received grant support from AstraZeneca and Schering-Plough/Merck; and has served on the Speakers' Bureaus of Sanofi-Aventis and Bristol-Myers Squibb. Dr. Kereiakes has received modest grant and/or research support from Abbott Vascular, Amylin Pharmaceuticals, and Boston Scientific; has received modest consulting fees from Eli Lilly, Boston Scientific, Abbott Vascular, Medpace, and REVA Medical Inc.; and has served on the Speakers' Bureau for Eli Lilly. Dr. Sibbing has received speaker fees from Dynabyte and The Medicines Company, as well as fees for advisory board activities from Eli Lilly. Dr. Trenk has received grants/research support from and served on the Speakers' Bureaus of Eli Lilly and Daiichi Sankyo Inc. Dr. Van Werkum has received speaker fees from Accumetrics and Siemens and has been a consultant for and served on the advisory board of The Medicines Company. Dr. Paganelli has received lecture fees from Sanofi-Aventis. Dr. Price has received research grants/support from Bristol-Myers Squibb/Sanofi-Aventis and Accumetrics and consulting and/or speaker fees from AstraZeneca, Daiichi Sankyo Inc./Eli Lilly, Bristol-Myers Squibb/Sanofi-Aventis, The Medicines Company, and Accumetrics. Dr. Waksman has received consulting and speaker fees from Biotronik, Medtronic, and Boston Scientific and research grants from Eli Lilly, Sanofi-Aventis/Bristol-Myers Squibb, Biotronik, Boston Scientific, The Medicines Company, GlaxoSmithKline, and Schering-Plough. Dr. Gurbel has received research grants from Schering-Plough, Millenium, AstraZeneca, National Institutes of Health, Hemoscope, Medtronic, Eli Lilly/Daiichi Sankyo Inc., Sanofi-Aventis, Portola, Bristol-Myers Squibb, Boston Scientific, Bayer, and Pozen; and honoraria from Schering-Plough, Portola, AstraZeneca, Bayer, and Medtronic. All other authors have reported that they have no relationships to disclose.

Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W. Belvedere Avenue, Baltimore, Maryland 21215. E-mail: pgurbel@lifebridgehealth.org.

REFERENCES

1. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. *N Engl J Med* 2004;350:277–80.
2. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. *J Clin Invest* 2004;113:340–5.
3. Gachet C. Regulation of platelet functions by P2 receptors. *Annu Rev Pharmacol Toxicol* 2006;46:277–300.
4. Patrono C, Baigent C, Hirsh J, Roth G, on behalf of American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133 Suppl 6:199S–233S.
5. Kushner FG, Hand M, Smith SC Jr., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2009;54:2205–41.
6. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation* 2003;107:2908–13.
7. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol* 2007;50:1822–34.
8. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. *J Am Coll Cardiol* 2005;45:1392–6.
9. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. *Eur Heart J* 2004;25:1903–10.
10. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. *Nat Clin Pract Cardiovasc Med* 2006;3:387–95.
11. Kuliczowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on Antiplatelet Drugs Resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. *Eur Heart J* 2009;30:426–35.
12. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. *Drug Metab Dispos* 2009;37:2145–52.
13. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. *Drug Metab Dispos* 2010;38:92–9.
14. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. *Drug Metab Dispos* 2002;30:1288–95.
15. Savi P, Zacharys JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. *Proc Natl Acad Sci U S A* 2006;103:11069–74.
16. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. *Am J Cardiol* 2006;98:681–4.
17. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. *Circulation* 2009;120:2577–85.
18. Simon T, Verstuyft C, Mary-Karuse M, et al., on behalf of French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* 2009;360:363–75.
19. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. *Circulation* 2005;111:2560–4.
20. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. *Circulation* 2008;118:1225–33.
21. Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. *Expert Opin Drug Metab Toxicol* 2009;5:989–1004.
22. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. *J Am Coll Cardiol* 2009;54:1041–57.

23. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. *Circulation* 2004;109:166–71.
24. Lau WC, Gurbel PA, Carville DG, et al. Saint John's wort enhances clopidogrel responsiveness in clopidogrel resistance volunteers and patients by induction of CYP3A4 isoenzymes (abstr). *J Am Coll Cardiol* 2007;49 Suppl:343A.
25. Bliden KP, DiChiara J, Lookman L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. *J Am Coll Cardiol* 2008;52:531–3.
26. Berger JS, Bhatt DL, Steinhilb SR, et al., on behalf of CHARISMA Investigators. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. *Circulation* 2009;120:2337–44.
27. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. *J Am Coll Cardiol* 2009;53:1273–8.
28. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. *J Am Coll Cardiol* 2008;51:256–60.
29. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. *J Clin Pharmacol* 2008;48:475–84.
30. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. *Am Heart J* 2009;157:148e1–5.
31. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. *Thromb Haemost* 2009;10:714–9.
32. Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? *Eur Heart J* 2009;30:1943–63.
33. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA* 2009;302:849–57.
34. Food and Drug Administration. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. FDA drug safety communication. Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm>. Accessed March 24, 2010.
35. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. *J Am Coll Cardiol* 2008;51:1925–34.
36. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* 2009;360:354–62.
37. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet* 2009;373:309–17.
38. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 2009;30:916–22.
39. Bhatt DL, Simonsen KL, Emison ES, et al., on behalf of the CHARISMA Executive Committee and Investigators. CHARISMA genomics. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009 Meeting; September 30, 2009; San Francisco, California.
40. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. *Diabetes* 2005;54:2430–5.
41. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? *J Invasive Cardiol* 2004;16:169–74.
42. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. *Blood Coagul Fibrinolysis* 2007;18:335–9.
43. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. *J Am Coll Cardiol* 2006;47:27–33.
44. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. *J Am Coll Cardiol* 2008;52:734–9.
45. Bliden KP, DiChiara J, Tantry US, Gurbel PA. Myonecrosis is predicted by lack of platelet inhibition measured by in response to multiple agonists in patients undergoing elective stenting: the risk of a global high platelet reactivity phenotype (abstr). *Circulation* 2007;116 Suppl:II517.
46. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. *Thromb Haemost* 2003;89:783–7.
47. Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. *Thromb Res* 2005;115:89–94.
48. Tantry US, Bliden KP, Gurbel PA. What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? *Catheter Cardiovasc Interv* 2005;66:597–8.
49. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. *Circulation* 2009;119:2625–32.
50. Labarthe B, Théroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. *J Am Coll Cardiol* 2005;46:638–45.
51. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. *Thromb Res* 2007;121:107–15.
52. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. *Haematologica* 2007;92:694–7.
53. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. *J Thromb Haemost* 2009;7:1029.
54. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? *J Am Coll Cardiol* 2007;49:657–66.
55. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. *J Am Coll Cardiol* 2005;46:1820–6.
56. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost* 2005;3:85–92.
57. Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. *J Intern Med* 2002;252:233–8.
58. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv* 2003;59:295–302.
59. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 2004;109:3171–5.
60. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatid to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatid to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. *Circulation* 2005;111:1153–9.
61. Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatid for elective stenting: effects on platelet function, thrombelastographic indices and their relation to periprocedural infarction: results of the CLEAR PLATELETS-2 study. *J Am Coll Cardiol* 2009;53:648–57.
62. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. *Thromb Haemost* 2007;98:1329–34.
63. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after

- stenting for non-ST elevation acute coronary syndromes. *Thromb Haemost* 2007;97:282-7.
64. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. *Thromb Haemost* 2007;98:838-43.
 65. Geisler T, Langer H, Wydimus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. *Eur Heart J* 2006;27:2420-5.
 66. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. *J Thromb Haemost* 2008;6:54-61.
 67. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. *J Am Coll Cardiol* 2006;48:1742-50.
 68. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. *Eur Heart J* 2008;29:992-1000.
 69. Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. *Platelets* 2008;19:595-604.
 70. Gurbel PA, Bliden KP, Samara W, et al. The clopidogrel Resistance and Stent Thrombosis (CREST) study. *J Am Coll Cardiol* 2005;46:1827-32.
 71. Buonamici P, Marcucci R, Miglironi A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. *J Am Coll Cardiol* 2007;49:2312-7.
 72. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. *J Thromb Haemost* 2007;5:1630-6.
 73. Cuisset T, Hamilos M, Sarma J, et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. *Am J Cardiol* 2008;101:1700-3.
 74. Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. *Circulation* 2009;120:2214-21.
 75. Marcucci R, Gori AM, Panizza R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. *Circulation* 2009;119:237-342.
 76. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. *J Am Coll Cardiol* 2008;51:1404-11.
 77. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. *Am J Cardiol* 2009;103:5-10.
 78. Valgimigli M, Campo G, de Cesare N, et al, on behalf of Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. *Circulation* 2009;119:3215-22.
 79. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. *J Am Coll Cardiol* 2008;52:1128-33.
 80. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol* 2009;53:849-56.
 81. Cuisset T, Frere C, Quilici J, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. *Am J Cardiol* 2009;104:1078-82.
 82. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. *JAMA* 2010;303:754-62.
 83. de Miguel Castro A, Cuellas Ramón C, Diego Nieto A, et al. Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. *Rev Esp Cardiol* 2009;62:126-35.
 84. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. *J Am Coll Cardiol* 2007;50:1541-7.
 85. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. *Circulation* 2007;115:708-16.
 86. von Beckerath N, Kastrati A, Wiecek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. *Eur Heart J* 2007;28:1814-9.
 87. Angiolillo DJ, Costa MA, Shoemaker SB, et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. *Am J Cardiol* 2008;101:440-5.
 88. Matetzky S, Fefer P, Shenkman B, Varon D, Savion N, Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. *Am J Cardiol* 2008;102:524-9.
 89. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. *J Am Coll Cardiol Intv* 2008;1:631-8.
 90. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. *J Am Coll Cardiol* 2009;53:1101-9.
 91. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. *J Am Coll Cardiol Intv* 2008;1:649-53.
 92. Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. *J Thromb Haemost* 2010;8:43-53.
 93. Gurbel PA, Bliden KP, Butler K, et al. REsponse to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies: the RESPOND Study. *Circulation* 2010;121:1188-99.
 94. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. *Am Heart J* 2009;157:818-24.
 95. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001-15.
 96. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
 97. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. *Eur Heart J* 2009;30:1753-63.
 98. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. *J Thromb Haemost* 2010;8:250-6.
 99. Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. *Eur Heart J* 2010;31:227-35.
 100. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? *Eurointervention* 2009;5:325-9.

Key Words: adenosine diphosphate ■ percutaneous coronary intervention ■ platelet reactivity ■ thrombotic events.